

20 August 2026

PACIFIC EDGE 2026 ANNUAL SHAREHOLDERS MEETING RESULTS

DUNEDIN, New Zealand – At Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) Annual Shareholders' Meeting, held on 20 August 2025, shareholders were asked to vote on six resolutions, which were supported by the Board.

As required by NZX Listing Rule 6.1, all voting was conducted by a poll. The resolutions passed by shareholders were:

- **Resolution 1:** To authorise the Directors to fix the auditor's remuneration for the ensuing year
- **Resolution 2:** That Bryan Williams, who retires in accordance with NZX Listing Rule 2.7.1 and is eligible for re-election, be re-elected as a Director of the Company
- **Resolution 3:** That Simon Flood, who retires in accordance with NZX Listing Rule 2.7.1 and is eligible for election, be elected as a Director of the Company
- **Resolution 4:** That the payment in cash of \$12,699 to Simon Flood, being unpaid Director remuneration that has accrued to him in respect of the period from 19 December 2025 to 31 March 2026 be approved for all purposes, including NZX Listing Rule 2.11.1
- **Resolution 5:** That the issue of 152,561,001 Shares under NZX Listing Rule 4.5.1, being Shares issued under the Placement, Shares issued to certain participants in the Retail Offer, and Shares issued in consideration for professional services provided in connection with the Placement and Retail Offer, be approved and ratified for all purposes, including NZX Listing Rule 4.5.1(c)
- **Resolution 6:** That the issue of 59,998,716 Shares under NZX Listing Rule 4.3.1(c), being Shares issued to certain participants in the Retail Offer, be approved and ratified for all purposes, including paragraph (a) of the definition of "share purchase plan" in the NZX Listing Rules

RESOLUTION:	FOR	AGAINST	ABSTAIN
1. Auditor's remuneration	660,399,757 (99.94%)	407,795 (0.06%)	854,630
2. Bryan Williams re-election	659,295,612 (99.69%)	2,075,767 (0.31%)	290,803
3. Simon Flood election	656,064,772 (99.90%)	665,264 (0.10%)	4,932,146
4. Payment to Simon Flood	655,195,114 (99.84%)	1,080,582 (0.16%)	803,275
5. Approval of share issue	401,524,695 (99.89%)	458,733 0.11%	48,919,882
6. Issue of shares to certain participants	610,586,164 (99.84%)	955,326 0.16%	50,120,692

As at the commencement of the meeting, Pacific Edge Limited had 1,241,852,687 total number of voting shares on issue.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

Investors:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: +64 22 032 1263

Media:

Richard Inder
The Project
P: +64 21 645 643

OVERVIEW

Pacific Edge: www.pacifiedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with hematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.